ZVRA FY2024 EPS Forecast Decreased by Cantor Fitzgerald

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($1.97) for the year, down from their prior forecast of ($1.61). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

ZVRA has been the subject of a number of other research reports. Roth Mkm raised their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday. JMP Securities started coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. Finally, Guggenheim began coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $8.62 on Monday. The company has a current ratio of 2.88, a quick ratio of 2.00 and a debt-to-equity ratio of 0.84. The stock has a 50 day simple moving average of $8.03 and a 200-day simple moving average of $6.50. The company has a market cap of $453.58 million, a price-to-earnings ratio of -4.38 and a beta of 1.93. Zevra Therapeutics has a 12-month low of $4.18 and a 12-month high of $9.21.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter last year, the business posted ($0.40) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. International Assets Investment Management LLC raised its position in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after buying an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the first quarter worth about $64,000. The Manufacturers Life Insurance Company boosted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $92,000. Finally, XTX Topco Ltd acquired a new position in shares of Zevra Therapeutics during the 3rd quarter valued at about $94,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.